PortfoliosLab logoPortfoliosLab logo
VIR vs. BBOT
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

VIR vs. BBOT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Vir Biotechnology, Inc. (VIR) and BridgeBio Oncology Therapeutics, Inc (BBOT). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, VIR achieves a 43.62% return, which is significantly higher than BBOT's -35.38% return.


VIR

1D
-2.70%
1M
-13.75%
6M
16.40%
YTD
43.62%
1Y
72.17%
3Y*
-15.28%
5Y*
-24.65%
10Y*
ALL TIME*
-8.75%

BBOT

1D
-4.82%
1M
-0.25%
6M
-30.97%
YTD
-35.38%
1Y
3Y*
5Y*
10Y*
ALL TIME*
*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison


PositionAvg. Volume Value (2W)Avg. Volume Value (1M)Avg. Volume Value (3M)
$2.40M$3.07M$3.39M
$13.61M$14.70M$17.41M

VIR vs. BBOT - Yearly Performance Comparison


2026 (YTD)2025
VIR
Vir Biotechnology, Inc.
43.62%40.89%
BBOT
BridgeBio Oncology Therapeutics, Inc
-35.38%22.75%

Correlation

The correlation between VIR and BBOT is 0.24, which is low. Their historical price movements had little consistent relationship.


Correlation
Correlation (All Time)
Calculated using the full available price history since Aug 12, 2025

0.24

Fundamentals

Market Cap

VIR:

$1.46B

BBOT:

$648.07M

EPS

VIR:

-$3.12

BBOT:

-$3.43

Total Revenue (TTM)

VIR:

$65.50M

BBOT:

$0.00

Gross Profit (TTM)

VIR:

$183.11M

BBOT:

-$194.00K

EBITDA (TTM)

VIR:

-$448.10M

BBOT:

-$168.31M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

VIR vs. BBOT — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

VIR
VIR Risk / Return Rank: 7979
Overall Rank
VIR Sharpe Ratio Rank: 7676
Sharpe Ratio Rank
VIR Sortino Ratio Rank: 7878
Sortino Ratio Rank
VIR Omega Ratio Rank: 7474
Omega Ratio Rank
VIR Calmar Ratio Rank: 8585
Calmar Ratio Rank
VIR Martin Ratio Rank: 8383
Martin Ratio Rank

BBOT

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

VIR vs. BBOT - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Vir Biotechnology, Inc. (VIR) and BridgeBio Oncology Therapeutics, Inc (BBOT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


VIRBBOTDifference
Sharpe ratioReturn per unit of total volatility

Sortino ratioReturn per unit of downside risk

Omega ratioGain probability vs. loss probability

1.22

Calmar ratioReturn relative to maximum drawdown

2.78

Martin ratioReturn relative to average drawdown

6.37

VIR vs. BBOT - Sharpe Ratio Comparison


Loading charts...

Drawdowns

VIR vs. BBOT - Drawdown Comparison

The maximum VIR drawdown since its inception was -94.85%, which is greater than BBOT's maximum drawdown of -48.14%. Use the drawdown chart below to compare losses from any high point for VIR and BBOT.


Loading charts...

Drawdown Indicators


VIRBBOTDifference

Max Drawdown

Largest peak-to-trough decline

-94.85%

-48.14%

-46.71%

Max Drawdown (1Y)

Largest decline over 1 year

-25.61%

Max Drawdown (3Y)

Largest decline over 3 years

-68.58%

Max Drawdown (5Y)

Largest decline over 5 years

-92.15%

Current Drawdown

Current decline from peak

-89.58%

-41.08%

-48.50%

Average Drawdown

Average peak-to-trough decline

-68.14%

-22.63%

-45.51%

Ulcer Index

Depth and duration of drawdowns from previous peaks

11.16%

Volatility

VIR vs. BBOT - Volatility Comparison


Loading charts...

Volatility by Period


VIRBBOTDifference

Volatility (1M)

Calculated over the trailing 1-month period

12.38%

Volatility (6M)

Calculated over the trailing 6-month period

45.20%

Volatility (1Y)

Calculated over the trailing 1-year period

69.13%

69.10%

+0.03%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

72.66%

69.10%

+3.56%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

95.40%

69.10%

+26.30%

Dividends

VIR vs. BBOT - Dividend Comparison

Neither VIR nor BBOT has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

VIR vs. BBOT - Financials Comparison

This section allows you to compare key financial metrics between Vir Biotechnology, Inc. and BridgeBio Oncology Therapeutics, Inc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items

Frequently Asked Questions


VIR and BBOT have a correlation of 0.24, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Portfolio Optimizer

Find the right allocation for VIR and BBOT

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer